title: Integrative radiogenomic profiling of squamous cell lung cancer.
abstract: Radiotherapy is one of the mainstays of anticancer treatment, but the relationship between the radiosensitivity of cancer cells and their genomic characteristics is still not well defined. Here, we report the development of a high-throughput platform for measuring radiation survival in vitro and its validation in comparison with conventional clonogenic radiation survival analysis. We combined results from this high-throughput assay with genomic parameters in cell lines from squamous cell lung carcinoma, which is standardly treated by radiotherapy, to identify parameters that predict radiation sensitivity. We showed that activation of NFE2L2, a frequent event in lung squamous cancers, confers radiation resistance. An expression-based, in silico screen nominated inhibitors of phosphoinositide 3-kinase (PI3K) as NFE2L2 antagonists. We showed that the selective PI3K inhibitor, NVP-BKM120, both decreased NRF2 protein levels and sensitized NFE2L2 or KEAP1-mutant cells to radiation. We then combined results from this high-throughput assay with single-sample gene set enrichment analysis of gene expression data. The resulting analysis identified pathways implicated in cell survival, genotoxic stress, detoxification, and innate and adaptive immunity as key correlates of radiation sensitivity. The integrative and high-throughput methods shown here for large-scale profiling of radiation survival and genomic features of solid-tumor-derived cell lines should facilitate tumor radiogenomics and the discovery of genotype-selective radiation sensitizers and protective agents.
authors: Authors' Affiliations: Harvard Radiation Oncology Program; Division of Medical Sciences, Harvard University; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School; Department of Medical Oncology, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute; Department of Pathology, Brigham and Women's Hospital, Boston; Chemical Biology Program; Howard Hughes Medical Institute, The Broad Institute of MIT and Harvard; Novartis Institute for Biomedical Research; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts; and Department of Medicine, Baylor College of Medicine, Houston, Texas.
authors: Mohamed E
authors: ME
authors: Abazeed
authors: Drew J
authors: DJ
authors: Adams
authors: Kristen E
authors: KE
authors: Hurov
authors: Pablo
authors: P
authors: Tamayo
authors: Chad J
authors: CJ
authors: Creighton
authors: Dmitriy
authors: D
authors: Sonkin
authors: Andrew O
authors: AO
authors: Giacomelli
authors: Charles
authors: C
authors: Du
authors: Daniel F
authors: DF
authors: Fries
authors: Kwok-Kin
authors: KK
authors: Wong
authors: Jill P
authors: JP
authors: Mesirov
authors: Jay S
authors: JS
authors: Loeffler
authors: Stuart L
authors: SL
authors: Schreiber
authors: Peter S
authors: PS
authors: Hammerman
authors: Matthew
authors: M
authors: Meyerson
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D048708:Cell Growth Processes / Q000235:genetics / Q000528:radiation effects; D045744:Cell Line, Tumor; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D051267:NF-E2-Related Factor 2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011836:Radiation Tolerance / Q000235:genetics
chemical_list: D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D000081082:Phosphoinositide-3 Kinase Inhibitors
references: Radiother Oncol. 1996 Aug;40(2):121-5
references: 8884965
references: Nat Rev Cancer. 2007 Jan;7(1):54-60
references: 17186018
references: Drug Metab Rev. 2001 Aug-Nov;33(3-4):255-71
references: 11768769
references: Antioxid Redox Signal. 2010 Dec 1;13(11):1627-37
references: 20446773
references: Cancer Res. 1999 Apr 1;59(7):1391-9
references: 10197600
references: Blood. 2008 Jun 15;111(12):5654-62
references: 18305216
references: J Exp Med. 1956 May 1;103(5):653-66
references: 13319584
references: J Clin Oncol. 2010 May 1;28(13):2181-90
references: 20351327
references: Radiother Oncol. 2000 Aug;56(2):197-207
references: 10927139
references: Cancer Cell. 2012 Jul 10;22(1):66-79
references: 22789539
references: Nat Genet. 2004 Mar;36(3):257-63
references: 14770183
references: Anticancer Res. 1998 Sep-Oct;18(5B):3685-8
references: 9854477
references: N Engl J Med. 2010 Oct 28;363(18):1693-703
references: 20979469
references: Radiat Res. 1982 Feb;89(2):255-63
references: 6278530
references: Science. 2006 Sep 29;313(5795):1929-35
references: 17008526
references: Cancer Res. 2008 Jan 15;68(2):415-24
references: 18199535
references: Tumour Biol. 2010 Aug;31(4):363-72
references: 20490962
references: Clin Cancer Res. 2009 Dec 15;15(24):7502-7509
references: 20008850
references: Cancer Cell. 2006 Oct;10(4):331-42
references: 17010674
references: Oncology. 2002;63 Suppl 2:29-38
references: 12466642
references: Nature. 2012 Mar 28;483(7391):603-7
references: 22460905
references: Cancer Lett. 1999 Jan 29;135(2):189-94
references: 10096428
references: Blood. 2010 Dec 23;116(26):5983-90
references: 20889920
references: Biochem Biophys Res Commun. 1997 Jul 18;236(2):313-22
references: 9240432
references: Int J Radiat Biol. 2011 Nov;87(11):1135-46
references: 21913819
references: Oncogene. 2007 May 10;26(21):2988-96
references: 17146442
references: Cancer Res. 2001 May 15;61(10):4278-82
references: 11358856
references: Clin Cancer Res. 2012 May 1;18(9):2443-51
references: 22407829
references: Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):988-96
references: 19251086
references: Cancer Res. 2010 Nov 1;70(21):8886-95
references: 20940400
references: Biochem Pharmacol. 2000 Jun 1;59(11):1433-9
references: 10751553
references: Nat Protoc. 2006;1(5):2315-9
references: 17406473
references: PLoS Med. 2007 Apr;4(4):e122
references: 17425403
references: Br J Cancer. 1987 Sep;56(3):287-93
references: 2822071
references: Cancer Res. 2005 Aug 15;65(16):7169-76
references: 16103067
references: Eur J Cancer Clin Oncol. 1989 Mar;25(3):527-34
references: 2539297
references: Nature. 2009 Nov 5;462(7269):108-12
references: 19847166
references: Cancer Cell. 2006 Oct;10(4):321-30
references: 17010675
references: J Biomol Screen. 2012 Aug;17(7):912-20
references: 22653913
references: Science. 2004 Jun 4;304(5676):1497-500
references: 15118125
references: Genes Dev. 2012 Jun 15;26(12):1268-86
references: 22713868
references: Free Radic Biol Med. 2011 Jun 15;50(12):1749-59
references: 21443946
references: Arch Biochem Biophys. 1999 Mar 1;363(1):98-106
references: 10049503
references: Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13568-73
references: 18757741
references: Genes Dev. 1999 Jan 1;13(1):76-86
references: 9887101
references: Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):497-505
references: 19735874
references: Assay Drug Dev Technol. 2012 Jun;10(3):235-49
references: 22192310
references: Nature. 2012 Sep 27;489(7417):519-25
references: 22960745
references: Oncogene. 2003 Sep 1;22(37):5866-75
references: 12947393